- M&A News
M&A News: Global M&A Deals Week of November 17 to 23, 2025
- IMAA
SHARE:
The Institute for Mergers, Acquisitions and Alliances (IMAA) provides a detailed weekly roundup of mergers and acquisitions news, highlighting the most significant global M&A deals. This essential update offers a snapshot of the latest movements and trends within the M&A market, showcasing the top transactions that stand out in the corporate world. Through this coverage, IMAA aims to furnish M&A professionals and enthusiasts alike with a comprehensive overview of the week’s M&A activities, helping them stay informed about the evolving landscape of global mergers and acquisitions.
The global mergers and acquisitions (M&A) market gained significant momentum during the week of November 17 to November 23, with 624 deals announced, representing a total deal value of USD 84.54 billion. Among these, 24 transactions exceeded USD 500 million each, contributing 78% of the week’s overall value, equivalent to USD 66.35 billion.
The standout deal of the week was Abbott’s USD 21 billion acquisition of Exact Sciences, marking a strategic move into the rapidly growing cancer diagnostics market. Exact Sciences, known for its expertise in early cancer detection and screening, will leverage Abbott’s broad primary care network to expand the reach of its flagship Cologuard test. Exact Sciences is expected to generate over USD 3 billion in revenue this year, and the acquisition is projected to elevate Abbott’s diagnostics segment beyond USD 12 billion annually, reinforcing its growing presence in cancer care.
The M&A landscape saw a 5% increase in deal volume from the previous week, rising from 595 to 624 deals, while total deal value jumped 73%, from USD 49.01 billion to USD 84.54 billion. This surge underscores a week of heightened strategic activity, driven by both large-cap acquisitions and sector-specific investments.
Top 5 M&A Deals for the Week
Here are the top 5 M&A Deals for the week of November 17 to 23, 2025 in detail:
Deal No. 1: Abbott Laboratories to Acquire Exact Sciences Corporation for USD 21.00 Billion
Deal No. 2: Akzo Nobel N.V. to Acquire Axalta Coating Systems Ltd. for USD 9.20 Billion
Deal No. 3: Clayton, Dubilier & Rice, LLC to Acquire Sealed Air Corporation for USD 6.20 Billion
Deal No. 4: Palo Alto Networks, Inc. to Acquire Chronosphere, Inc.for USD 3.35 Billion
Deal No. 5: Johnson & Johnson to Acquire Halda Therapeutics Inc. for USD 3.05 Billion
Deal No. 1:
Abbott Laboratories to Acquire Exact Sciences Corporation for USD 21.00 Billion
Global healthcare company Abbott has announced its acquisition of Exact Sciences in a USD 21 billion deal, making it one of Abbott’s largest transactions in nearly a decade. The move strengthens Abbott’s presence in diagnostics and expands its footprint into oncology-focused testing.
Exact Sciences is a molecular diagnostics company known for its non-invasive cancer screening technologies. Its portfolio includes established products like Cologuard and Oncotype DX, alongside newer innovations such as Cancerguard for multi-cancer early detection and Oncodetect for monitoring molecular residual disease and recurrence. The company uses advanced DNA and biomarker analysis to improve the accuracy and accessibility of early cancer detection, supporting better patient outcomes.
The company is expected to generate more than USD 3 billion in revenue this year and perform over 5 million tests, with the majority of its operations concentrated in the United States.
The purchase introduces a new vertical for Abbott, providing a strong foothold in the fast-growing USD 60 billion U.S. cancer-screening and precision oncology diagnostics market. Combined, the companies aim to accelerate innovation, broaden access to advanced diagnostics, and help more patients detect and manage cancer at earlier, more treatable stages.
The transaction is targeted to close in the second quarter of 2026. Morgan Stanley is acting as Abbott’s exclusive financial advisor, while Centerview Partners LLC and XMS Capital Partners, LLC are advising Exact Sciences.
Deal No. 2:
Akzo Nobel N.V. to Acquire Axalta Coating Systems Ltd. for USD 9.20 Billion
Dutch paint and coatings firm AkzoNobel is acquiring Axalta Coating Systems in a USD 9.2 billion deal, creating a global coatings leader with an enterprise value of USD 25 billion.
Axalta Coating Systems is a worldwide coatings company specializing in liquid and powder solutions for vehicles, industrial equipment, and architectural applications. The company provides advanced coatings to automotive OEMs and refinish markets, emphasizing durability, corrosion protection, and visual quality across industries including transportation, construction, and industrial manufacturing. With more than 150 years of experience, Axalta serves over 100,000 customers in more than 130 countries.
Under the merger, AkzoNobel shareholders will own 55% of the combined entity, and Axalta investors 45%. AkzoNobel will issue a EUR 2.5 billion special cash dividend, and both companies will contribute four directors each to the board, alongside three independent members.
The combined business will operate in over 160 countries and is expected to generate USD 600 million in run-rate synergies, with approximately 90% realized within three years of closing. The merger unites AkzoNobel’s and Axalta’s complementary portfolios to deliver a comprehensive range of coatings solutions, covering Powder, Aerospace, Refinish, Mobility, Marine and Protective, Industrial Coatings, and Decorative Paints, supported by around 100 recognized brands.
The deal is expected to close between late 2026 and early 2027, with the new company adopting a new name and ticker symbol and maintaining dual headquarters in Amsterdam and Philadelphia. Morgan Stanley advises AkzoNobel, while Evercore and J.P. Morgan Securities serve as financial advisors to Axalta.
Deal No. 3:
Clayton, Dubilier & Rice, LLC to Acquire Sealed Air Corporation for USD 6.20 Billion
Sealed Air Corporation, a global leader in packaging solutions, is being acquired by private equity firm Clayton, Dubilier & Rice (CD&R) in an all-cash transaction valued at USD 6.2 billion, taking the company private.
Sealed Air provides integrated packaging solutions combining sustainable, high-performance materials, automation, equipment, and services. Known for its iconic Bubble Wrap, the company develops innovative materials and automated systems that enhance product safety, extend shelf life, and optimize supply chains across industries such as food and beverage, e-commerce, healthcare, and consumer goods. In 2024, Sealed Air generated USD 5.4 billion in revenue and employs around 16,400 people serving customers in 117 countries and territories.
CD&R brings extensive experience in the industrial and packaging sectors. Its partnership is expected to support Sealed Air’s continued investment in its Food and Protective packaging segments and accelerate its next phase of growth, while maintaining a customer-focused approach.
The transaction is anticipated to close in mid-2026. Evercore served as exclusive financial advisor to Sealed Air, while BofA Securities, BNP Paribas, Citi, Goldman Sachs, J.P. Morgan, Lazard, Mizuho, RBC Capital Markets, UBS Investment Bank, and Wells Fargo advised CD&R.
Deal No. 4:
Palo Alto Networks, Inc. to Acquire Chronosphere, Inc.for USD 3.35 Billion
Palo Alto Networks is broadening its data and security portfolio to meet the escalating demands of the AI era through its USD 3.35 billion acquisition of Chronosphere.
Chronosphere is a cloud-native observability platform engineered for large-scale, containerized, and modern cloud environments. It empowers engineering teams to monitor metrics, logs, and traces efficiently, reduce telemetry costs, and quickly pinpoint and resolve operational issues. Built to handle the intensive data workloads of AI applications, Chronosphere supports open standards such as OpenTelemetry and Prometheus, enabling scalable, high-performance observability.
Palo Alto Networks intends to integrate Chronosphere’s technology with Cortex AgentiX, its AI-driven autonomous remediation platform, strengthening its ability to offer organizations a unified, secure, and data-centric infrastructure capable of supporting both modern applications and AI workloads.
The transaction is expected to close in the second half of Palo Alto’s FY 2026. This move follows a string of strategic acquisitions, including the USD 25 billion deal to acquire CyberArk announced in July 2025.
Deal No. 5:
Johnson & Johnson to Acquire Halda Therapeutics Inc. for USD 3.05 Billion
Johnson & Johnson has agreed to acquire Halda Therapeutics in an all-cash transaction valued at USD 3.05 billion, securing a promising clinical-stage therapy for prostate cancer.
Halda Therapeutics is a clinical-stage biotechnology company developing a novel class of targeted cancer therapies through its proprietary RIPTAC™ platform. The platform brings a tumor-specific protein into proximity with a critical survival protein, selectively disabling it and inducing cancer cell death. Its lead candidate, HLD‑0915, is an oral therapy currently in clinical trials for prostate cancer, with global new diagnoses projected to reach 1.7 million by 2030. Halda’s pipeline also includes early-stage programs targeting breast, lung, and other solid tumors.
The acquisition strengthens Johnson & Johnson’s oncology portfolio, building on nearly two decades of innovation in prostate cancer while introducing a mechanism of action that may help overcome resistance to existing therapies. Halda’s differentiated pipeline, if successful, could provide new treatment options for patients with significant unmet needs.
The transaction is expected to close in the coming months. Centerview Partners LLC is serving as the exclusive financial advisor to Halda.
This concludes our M&A news coverage of the top global mergers and acquisitions deals for the week of November 17 to 23, 2025. For continuous and detailed insights into the evolving landscape of M&A news, we invite you to follow the Institute for Mergers, Acquisitions, and Alliances (IMAA).
More M&A News
Stay up to date with M&A news!
Subscribe to our newsletter